These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study. Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B. Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126 [Abstract] [Full Text] [Related]
5. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B. Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962 [Abstract] [Full Text] [Related]
6. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)]. Golubchik P, Sever J, Weizman A. Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124 [Abstract] [Full Text] [Related]
8. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment]. Oberpichler-Schwenk H. Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689 [No Abstract] [Full Text] [Related]
19. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137 [Abstract] [Full Text] [Related]